Merck posts Q2 GAAP loss of $5.98B on $10.2B Prometheus charge; raises FY sales outlook

Merck & Co., Inc.

2023-Q2 EPS reported -$1.24 revenue$29,522,000,000

GAAP loss per share of $2.35 on net loss of $5,975M; includes $4.02/share charge for Prometheus acquisition.
Total sales $15,035M (+3% YoY); excluding LAGEVRIO, sales grew 11% (+14% ex-FX).
KEYTRUDA sales $6,271M (+19% YoY); GARDASIL/GARDASIL 9 sales $2,458M (+47% YoY).
LAGEVRIO sales fell 83% to $203M; non-GAAP EPS loss of $2.06 vs. $1.87 gain a year ago.
FY 2023 sales outlook raised to $58.6-59.6B; non-GAAP EPS outlook $2.95-3.05 (includes -$4.53/share one-time charges).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Merck & Co., Inc. reported the second quarter of 2023 results: revenue $15.0 Billion, net income $(5,975) million, EPS ($2.35) per share. Guidance raised.

Period: the second quarter of 2023
Revenue: $15.0 Billion
Net income: $(5,975) million
EPS: ($2.35) per share
Guidance: raised
Result: reported results

Exact text from the filing

Merck Announces Second-Quarter 2023 Financial Results - Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines - Total Worldwide Sales Were $15.0 Billion, an Increase of 3% From Second Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 14% ○ KEYTRUDA Sales Grew 19% to $6.3 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% ○ GARDASIL/GARDASIL 9 Sales Grew 47% to $2.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 53% ○ LAGEVRIO Sales Declined 83% to $203 Million; Excluding the Impact of Foreign Exchange, Sales Declined 82% - GAAP Loss per Share Was $2.35; Non-GAAP Loss per Share Was $2.06; GAAP and Non-GAAP Loss per Share Include a Charge of $4.02 per Share for the Acquisition of Prometheus - Presented Compelling Data in Earlier Stages of Cancer at 2023 ASCO Annual Meeting, Including: o Positive Phase 3 Results From KEYNOTE-671 Trial o Promising New Data From Phase 2

View on SEC.gov

Browse all earnings releases →

Merck & Co., Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-086030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.